ATRION Co. Announces Quarterly Dividend of $1.20 (ATRI)

ATRION Co. (NASDAQ:ATRI) announced a quarterly dividend on Tuesday, May 22nd, RTT News reports. Shareholders of record on Friday, June 15th will be given a dividend of 1.20 per share by the medical instruments supplier on Friday, June 29th. This represents a $4.80 annualized dividend and a dividend yield of 0.80%.

ATRION has increased its dividend payment by an average of 17.4% per year over the last three years and has increased its dividend every year for the last 15 years.

Shares of ATRI traded down $1.60 during midday trading on Tuesday, hitting $598.00. The stock had a trading volume of 111 shares, compared to its average volume of 7,614. ATRION has a twelve month low of $516.85 and a twelve month high of $694.00. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of 31.44 and a beta of 0.67.

ATRION (NASDAQ:ATRI) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share (EPS) for the quarter. The firm had revenue of $34.02 million for the quarter. ATRION had a return on equity of 19.34% and a net margin of 23.82%.

Separately, BidaskClub upgraded ATRION from a “strong sell” rating to a “sell” rating in a report on Thursday, March 29th.


Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Dividend History for ATRION (NASDAQ:ATRI)

Receive News & Ratings for ATRION Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRION and related companies with's FREE daily email newsletter.

Leave a Reply